Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial
Simone Ferrero(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Antonio Pezzutto(Charité - Universitätsmedizin Berlin), Paola Ghione(University of Turin), Roswitha Forstpointner(LMU Klinikum), Ulrich Keller(Humboldt-Universität zu Berlin), Jürgen Finke(University Medical Center Freiburg), Martin Dreyling(LMU Klinikum), Oliver Weigert(German Cancer Research Center), Lothar Bergmann(Universität Ulm), Roberto Passera(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Christian W. Scholz(MSB Medical School Berlin), Wolfgang Hiddemann(Christian-Albrechts-Universität zu Kiel), Michael Unterhalt, Alessandro Pastore(Memorial Sloan Kettering Cancer Center), Lorenz Trümper(University of Göttingen)
Cited by 12
Related Papers
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
|The Lancet Oncology|2008|1.1k
A Biologic Definition of Burkitt's Lymphoma from Transcriptional and Genomic Profiling
|New England Journal of Medicine|2006|1k